Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

64.50EUR
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
€64.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,523,320
52-wk High
€92.97
52-wk Low
€63.09

Latest Key Developments (Source: Significant Developments)

Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Bioverativ Inc ::BIOVERATIV SAYS REGARDING TERMINATION OF MERGER DEAL WITH SANOFI UNDER CERTAIN CIRCUMSTANCES CO WILL BE REQUIRED TO PAY FEE OF $326 MILLION - SEC FILING.  Full Article

Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Sanofi Chief financial officer Jerome Contamine says ::sees commercial, cost and tax synergies related to the acquisition of U.S firm Bioverativ by France's Sanofi .  Full Article

Regeneron Announces Approval Of Dupixent (Dupilumab) In Japan For Treatment Of Atopic Dermatitis
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON ANNOUNCES APPROVAL OF DUPIXENT® (DUPILUMAB) IN JAPAN FOR THE TREATMENT OF ATOPIC DERMATITIS.REGENERON PHARMACEUTICALS - DUPIXENT IS BEING JOINTLY DEVELOPED BY CO, SANOFI UNDER A COLLABORATION AGREEMENT, & WILL BE COMMERCIALIZED IN JAPAN BY SANOFI.  Full Article

Sanofi nears deal to buy Hemophilia drugmaker Bioverativ for over $11.5 bln - WSJ
Monday, 22 Jan 2018 

Jan 21 (Reuters) - :SANOFI NEARS DEAL TO BUY HEMOPHILIA DRUGMAKER BIOVERATIV FOR MORE THAN $11.5 BILLION - WSJ, CITING SOURCES‍​.  Full Article

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - AR101 BLA SUBMISSION EXPECTED AT END OF 2018.AIMMUNE THERAPEUTICS ANNOUNCES 2018 OUTLOOK, INCLUDING UPCOMING DATA FROM PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ARTEMIS TRIAL IS ON TRACK TO COMPLETE ENROLLMENT IN Q1 OF 2018, EXPECTS DATA FROM ARTEMIS IN EARLY 2019.AIMMUNE THERAPEUTICS INC - ENDED 2017 WITH ABOUT $182 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017.AIMMUNE THERAPEUTICS INC- 2018 PLANS INCLUDE INITIATION OF ARC005 CLINICAL TRIAL OF AR101 FOR PEANUT ALLERGY IN YOUNG CHILDREN AGES 6-48 MONTHS.AIMMUNE THERAPEUTICS - 2018 PLANS ALSO INCLUDE INITIATION, WITH REGENERON AND SANOFI, OF PHASE 2 CLINICAL TRIAL OF AR101 AND ADJUNCTIVE DUPILUMAB.AIMMUNE - ALSO EXPECTS TO FILE IND APPLICATION FOR EGG ALLERGY PROGRAM IN 2018, CONTINUE WORK TOWARD FILING IND FOR WALNUT ALLERGY IN 2019.  Full Article

Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​.REGENERON PHARMACEUTICALS-PURSUANT TO LETTER AGREEMENT, CO, SANOFI SAS, AGREED TO INCREASE REGN2810 BUDGET AMOUNT TO $1.640 BILLION.REGENERON -ENTERED LETTER AGREEMENT ALSO RELATING TO AMONG OTHERS​, THE INVESTOR AGREEMENT DATED AS OF JAN 11, 2014, WITH SANOFI - SEC FILING.REGENERON PHARMACEUTICALS INC - ‍ ALSO AGREED TO REVISE REGN2810 GLOBAL DEVELOPMENT PLAN AND REGN2810 GLOBAL DEVELOPMENT BUDGET.  Full Article

Sanofi And Alnylam Pharmaceuticals Enter Into Partnership
Monday, 8 Jan 2018 

Jan 8 (Reuters) - SANOFI SA ::AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE.SANOFI WILL OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO FITUSIRAN.GLOBAL COMMERCIALIZATION OF FITUSIRAN, UPON APPROVAL, WILL BE DONE BY SANOFI GENZYME.ALNYLAM WILL RECEIVE ROYALTIES BASED ON NET SALES OF FITUSIRAN PRODUCTS.ALNYLAM TO OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ITS INVESTIGATIONAL RNAI THERAPEUTICS PROGRAMS FOR THE TREATMENT OF ATTR AMYLOIDOSIS, INCLUDING PATISIRAN AND ALN-TTRSC02.SANOFI WILL RECEIVE ROYALTIES BASED ON NET SALES OF THESE ATTR AMYLOIDOSIS PRODUCTS.  Full Article

Evotec, Apeiron Biologics receive milestone payment from Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.  Full Article

Sanofi Joins Forces With BIOASTER To Improve The Search For Next-Generation Vaccine Candidates
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - SANOFI ::JOINS FORCES WITH BIOASTER TO IMPROVE THE SEARCH FOR NEXT-GENERATION VACCINE CANDIDATES.  Full Article

‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Sanofi statement::Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis.‍Patisiran Marketing Authorization Application to be reviewed under accelerated assessment.Sanofi Genzyme is currently preparing regulatory filings for patisiran in Japan, Brazil and other countries, with submissions expected to begin in the first half of 2018. .Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world, including certain Central and Eastern European countries of the European Union. .​.  Full Article

BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​

* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES